Chargement en cours...
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
Progress in the development of new therapies for cystic fibrosis (CF) has benefitted from therapeutically responsive biomarkers to streamline drug development. Paradoxically, these response biomarkers have proven to be essential even in the presence of data demonstrating a lack of correlation with c...
Enregistré dans:
| Publié dans: | Trends Mol Med |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708517/ https://ncbi.nlm.nih.gov/pubmed/32868171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmed.2020.08.002 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|